Critical assessment of thioguanine treatment for inflammatory bowel diseases: Is it time to rehabilitate this treatment?

about

Critical assessment of thioguanine treatment for inflammatory bowel diseases: Is it time to rehabilitate this treatment?

Item

http://www.wikidata.org/entity/Q48188262

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Critical assessment of thiogua ...... o rehabilitate this treatment?

@en

Critical assessment of thiogua ...... o rehabilitate this treatment?

@nl

type

Item

label

Critical assessment of thiogua ...... o rehabilitate this treatment?

@en

Critical assessment of thiogua ...... o rehabilitate this treatment?

@nl

prefLabel

Critical assessment of thiogua ...... o rehabilitate this treatment?

@en

Critical assessment of thiogua ...... o rehabilitate this treatment?

@nl

P1476

Critical assessment of thiogua ...... o rehabilitate this treatment?

@en

P2093

Alison Haywood

http://www.w3.org/2001/XMLSchema#string

Ramya Movva

http://www.w3.org/2001/XMLSchema#string

Sohil A Khan

http://www.w3.org/2001/XMLSchema#string

Timothy Hj Florin

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

A novel mouse model of veno-occlusive disease provides strategies to prevent thioguanine-induced hepatic toxicity

6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients.

Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease.

Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.

Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?

On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients

Current limitations of IBD treatment: where do we go from here?

Thiopurines in inflammatory bowel disease revisited

P304

529-536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1751-2980.12536

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Iulia Oancea

P577

2017-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28834232

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases